Table 1.
Summary of core baseline demographics and baseline characteristics of all patients receiving at least one dose of pasireotide in the extension study
| Overall population (n = 30) | |
|---|---|
| Age (years) | |
| Median (range) | 45.1 (21–84) |
| Sex | |
| Female, n (%) | 16 (53.3) |
| Race, n (%) | |
| Caucasian | 26 (86.7) |
| Other | 4 (13.3) |
| Previous treatment for acromegaly, n (%) | |
| De novoa | 4 (13.3) |
| Previous somatostatin analogue treatment | 22 (73.3) |
| Previous surgery | 19 (63.3) |
| Previous radiotherapy | 6 (20.0) |
| Time since diagnosis (years)b | |
| <1 | 5 (16.7) |
| 1 to <5 | 12 (40.0) |
| 5 to <10 | 7 (23.3) |
| ≥10 | 6 (20.0) |
aNo prior medical, radiation or surgical treatment for acromegaly
bTime between diagnosis of acromegaly and the beginning of the core study